Cipher Pharmaceuticals (DE:PHE)
FRANKFURT:PHE
PHE Stock Chart & Stats
€9.20
€0.05(0.51%)
At close: 4:00 PM EST
€9.20
€0.05(0.51%)
Day’s Range― - ―
52-Week Range€7.00 - €12.20
Previous CloseN/A
Volume0.00
Average Volume (3M)36.00
Market Cap
€261.85M
Enterprise Value€301.19M
Total Cash (Recent Filing)€6.41M
Total Debt (Recent Filing)€428.30K
Price to Earnings (P/E)9.7
Beta-0.24
Next Earnings
Aug 06, 2026EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.22
Shares Outstanding25,281,181
10 Day Avg. Volume59
30 Day Avg. Volume36
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.22
Price to Sales (P/S)5.44
P/FCF Ratio9.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.67Price Target Upside48.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.54
Revenue Forecast (FY)€33.26M
Bulls Say, Bears Say
Bulls Say
Cash GenerationCipher's free cash flow grew materially (TTM FCF growth ~77%) and operating cash closely tracks reported profit (near 1:1 in multiple periods). Strong, repeatable cash generation supports reinvestment in commercialization, licensing deals, and reduces reliance on external financing, enhancing long-term operational flexibility.
High ProfitabilityExceptionally high gross and net margins (TTM net margin ~54%) indicate durable pricing power or favorable product economics in Cipher's specialty portfolio. Sustained margin levels support healthy internal returns, fund business development, and provide buffer against reimbursement pressure, bolstering long-term earnings quality.
Conservative Balance SheetVery low leverage (debt-to-equity ~0.04) and a growing equity base give Cipher financial optionality for licensing, acquisitions, or supporting commercial growth. A conservative capital structure reduces refinancing risk and preserves capacity to invest in product launches or partner arrangements over the medium term.
Bears Say
Profitability VolatilityYear-to-year swings in net margin suggest results may be driven by non-recurring items, product mix shifts, or timing effects rather than steady operating improvement. This volatility complicates forecasting, weakens the predictability of cash flow for reinvestment, and raises execution risk for longer-term planning.
Variable Debt LevelsLarge swings in debt between years indicate management uses leverage episodically, which can mask underlying financing needs. Such variability complicates assessment of financial risk, could increase interest or refinancing exposure in adverse markets, and makes capital structure less predictable for investors.
Small Employee BaseCipher's very small headcount (5 employees) implies heavy reliance on partners, third-party manufacturers, and external commercialization resources. Limited internal scale can constrain the company's ability to execute multiple launches simultaneously and raises operational dependency and execution risk over the medium term.
Cipher Pharmaceuticals News
PHE FAQ
What was Cipher Pharmaceuticals’s price range in the past 12 months?
Cipher Pharmaceuticals lowest stock price was €7.00 and its highest was €12.20 in the past 12 months.
What is Cipher Pharmaceuticals’s market cap?
Cipher Pharmaceuticals’s market cap is €261.85M.
When is Cipher Pharmaceuticals’s upcoming earnings report date?
Cipher Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 63 days.
How were Cipher Pharmaceuticals’s earnings last quarter?
Cipher Pharmaceuticals released its earnings results on May 07, 2026. The company reported €0.206 earnings per share for the quarter, beating the consensus estimate of €0.116 by €0.09.
Is Cipher Pharmaceuticals overvalued?
According to Wall Street analysts Cipher Pharmaceuticals’s price is currently Undervalued.
Does Cipher Pharmaceuticals pay dividends?
Cipher Pharmaceuticals does not currently pay dividends.
What is Cipher Pharmaceuticals’s EPS estimate?
Cipher Pharmaceuticals’s EPS estimate is 0.18.
How many shares outstanding does Cipher Pharmaceuticals have?
Cipher Pharmaceuticals has 25,281,181 shares outstanding.
What happened to Cipher Pharmaceuticals’s price movement after its last earnings report?
Cipher Pharmaceuticals reported an EPS of €0.206 in its last earnings report, beating expectations of €0.116. Following the earnings report the stock price went up 10%.
Which hedge fund is a major shareholder of Cipher Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:PHE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cipher Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€13.67 (48.61% Upside)
€13.67 (48.61% Upside)
Insider Transactions
Sold Shares
Worth €80.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.29%
12-Months-Change
Fundamentals
Return on Equity
25.69%
Trailing 12-Months
Asset Growth
-6.01%
Trailing 12-Months
Company Description
Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.
PHE Company Deck
PHE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and significant debt reduction, supported by the robust performance of the Natroba business. However, challenges remain in licensing revenue and the Absorica portfolio, along with increased SG&A costs. Overall, the positive aspects slightly outweigh the negative aspects.View all DE:PHE earnings summariesPHE Stock 12 Month Forecast
Average Price Target
€13.67
▲(48.61% Upside)
Technical Analysis
Knight Therapeutics
―
Medexus Pharmaceuticals Inc
―
Biosyent
―
HLS Therapeutics Inc
―
Cardiol Therapeutics
―
Options Prices
Currently, No data available
---